Article
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.
Oncogene - 6 Jan 2000
Fueyo J, Gomez-Manzano C, Alemany R, Lee P S, McDonnell T J, Mitlianga P, Shi Y X, Levin V A, Yung W K, Kyritsis A P
Abstract excerpt
Effective anti cancer strategies necessitate the use of agents that target tumor cells rather than normal tissues. In this study, we constructed a tumor-selective adenovirus, Delta24, that carries a 24-bp deletion in the E1A region responsible for binding Rb protein. Immunoprecipitation analyses verified that this deletion rendered Delta24 unable to bind the Rb protein. However, titration experiments in 293 cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.